Nektar Therapeutics (NKTR) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$270.2 million.
- Nektar Therapeutics' Enterprise Value fell 1051.68% to -$270.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$270.2 million, marking a year-over-year decrease of 1051.68%. This contributed to the annual value of -$255.2 million for FY2024, which is 1593.79% up from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Enterprise Value is -$270.2 million, which was down 1051.68% from -$175.9 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Enterprise Value ranged from a high of -$175.9 million in Q2 2025 and a low of -$1.0 billion during Q1 2021
- For the 5-year period, Nektar Therapeutics' Enterprise Value averaged around -$489.3 million, with its median value being -$409.4 million (2023).
- As far as peak fluctuations go, Nektar Therapeutics' Enterprise Value surged by 4067.97% in 2022, and later plummeted by 1051.68% in 2025.
- Nektar Therapeutics' Enterprise Value (Quarter) stood at -$734.0 million in 2021, then skyrocketed by 31.2% to -$505.0 million in 2022, then skyrocketed by 39.88% to -$303.6 million in 2023, then rose by 15.94% to -$255.2 million in 2024, then fell by 5.87% to -$270.2 million in 2025.
- Its Enterprise Value stands at -$270.2 million for Q3 2025, versus -$175.9 million for Q2 2025 and -$218.6 million for Q1 2025.